Dr Sethupathi Muthuramalingam
MBBS, MD, FRCP(UK)
I graduated from India and obtained an MD in General Medicine from one of the prestigious central institutes (JIPMER) in India. I was awarded a Gold medal by the University for the most outstanding performance in the MD examination.
My general oncology training started in the Republic of Ireland and then I spent fours years in the Oxford Medical Oncology training programme, leading to the completion of specialist training in oncology. I took part in various research activities during my training and I was awarded the American Society of Oncology Merit Award for the quality research paper abstract submitted in one of their meetings.
In 2005 I was appointed as a Consultant Medical Oncologist at Portsmouth Hospitals NHS Trust. As an oncologist with a special interest in colorectal, lung cancer and mesothelioma, my expertise is treating cancer patients with chemotherapy, biological therapies, targeted therapies and also immunotherapies. I also use molecular tests like next generation sequencing (NGS) and genetic tests to guide treatment decisions and reduce the toxicities from treatment. In addition, I take part in many clinical trials and I was the principal investigator of a few of the trials. I have extensive knowledge in managing symptoms associated with cancer and I work very closely with the palliative care and pain team.
Some of the principal treatments carried out by Dr Sethupathi Muthuramalingam at Spire include:
COVID-19 testing or antibody tests are not available as a standalone service at Spire Portsmouth Hospital.
Lead for the chemotherapy services: 2009-2016 Portsmouth Hospitals NHS trust
Lead for the chemotherapy Governance and peer reviews: 2009-2016
Represented Portsmouth in the network chemotherapy network meetings: 2009-2016
Represented chemotherapy services in the Formulary Medicines Group meetings: 2011-2016 Portsmouth Hospitals NHS trust
Chair of the oncology Consultant group meetings: 2013-2014
Portsmouth Representative: 2011-2013 Regional ‘Cancer Drugs and Therapeutics Evaluation committee’ (CDTEC) meeting
Consultant Medical Oncologist, Portsmouth Haematology Oncology Centre, Queen Alexandra Hospital, Portsmouth.